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Microvesicles, small membrane vesicles released from cells, have beneficial and/or
deleterious effects in sepsis. We previously reported that non-muscle myosin light
chain kinase (nmMLCK) deletion protects mice against endotoxic shock by reducing
inflammation. Here, we have evaluated the consequences of nmMLCK deletion
on microvesicle phenotypes and their effects on mouse aortic endothelial cells in
association with vascular inflammation and endothelial dysfunction during endotoxic
shock induced by lipopolysaccharide in mice. Treatment with lipopolysaccharide
induced an increase in levels of circulating microvesicles in wild type but not in
nmMLCK-deficient mice. Microvesicles from nmMLCK-deficient mice (MVsnmMLCK−/−)
prevented the inflammatory effects of lipopolysaccharide with concomitant increase
of anti- inflammatory and reduction of pro-inflammatory secretome in mouse aortic
endothelial cells. In addition, MVsnmMLCK−/− reduced the efficacy of lipopolysaccharide
to increase aortic oxidative and nitrosative stresses as well as macrophage infiltration
in the aorta. Moreover, MVsnmMLCK−/− prevented ex vivo endothelial dysfunction,
vascular hyporeactivity, and in vivo overproduction of nitric oxide in heart and liver
in response to lipopolysaccharide. Altogether, these findings provide evidence that
nmMLCK deletion generates circulating microvesicles displaying protective effects by
activating endothelial pro-resolving anti-inflammatory pathways allowing the effective
down-regulation of oxidative and nitrative stresses associated with endotoxic shock.
Thus, nmMLCK plays a pivotal role in susceptibility to sepsis via the control of cellular
activation and release of circulating microvesicles.
Keywords: endothelial cells, extracellular vesicles, lipopolysaccharide, nmMLCK
Abbreviations: AoECs, aorta endothelial cells; DHE, dihydroethidine; iNOS, inducible nitric oxide synthase; IGFBP-3,
insulin like growth factor binding protein 3; MVs, microvesicles; MVsnmMLCK+/+, microvesicles from wild type mice;
MVsnmMLCK−/−, microvesicles from nmMLCK deficient mice; MLC-2, myosin light chain; nmMLCK, non-muscle myosin
light chain kinase; PFP, platelet-free plasma; 5-HT, serotonin; SDF-1α, stromal cell-derived factor 1 alpha; TARC, thyroid
activation regulated chemokine.
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INTRODUCTION
Sepsis is defined as a clinical syndrome characterized by
a systemic inflammatory response to infection that leads
to microvascular thrombosis, vascular hyporeactivity, and
endothelial dysfunction resulting in multiple organ dysfunction
(Annane et al., 2005; Schouten et al., 2008). Treatment of sepsis
is still a clinical challenge in cardiovascular medicine. Among
the potential new targets for sepsis therapy, a new protein
has been found to play an important role during endotoxic
shock in different experimental models of sepsis (Ralay Ranaivo
et al., 2007). This protein, the nmMLCK, belongs to a family
of protein kinases whose main function is to phosphorylate
the 20 kDa regulatory MLC-2 at Ser-19 for ATPase driven
actin-myosin contraction. nmMLCK is expressed in endothelial
cells, epithelium, platelets, and neutrophils (Verin et al., 1998;
Signorello et al., 2013). nmMLCK plays a significant role in the
maintenance of endothelial barrier function by controlling the
permeability of tight junctions and leukocyte transmigration (Ma
et al., 2005; Vandenbroucke et al., 2008). Previously, we showed
that nmMLCK knockout mice have lower susceptibility to septic
injury and these mice present an improving of survival curve,
protection against vascular hyporeactivity, as well as nitrative
and oxidative stress associated to endotoxic shock, suggesting
a protective role of nmMLCK deletion (Ralay Ranaivo et al.,
2007).
Systemic inflammation is orchestrated by interactions between
inflammatory cells and target cells by various means of cellular
communication such as MVs. MVs represent a circulating
reservoir of bioactive molecules displaying multiple functions
(coagulation, fibrinolysis, inflammation, and angiogenesis) which
are able to carry biological information. Enhanced levels of
circulating MVs from platelets, granulocytes, and endothelial
cells have been described in patients with meningococcal
septicemia, and septic shock (Nieuwland et al., 2000; Fujimi et al.,
2002; Mostefai et al., 2008). MVs from septic shock patients
exert pleiotropic and differential effects. Indeed, platelet- and
leukocyte-derived MVs have procoagulant effects with thrombin
generation occurring via a tissue factor VIIa-dependent pathway;
this may account to microvascular thrombosis in septic patients
(Nieuwland et al., 2000). Accordingly with this, inoculation
of septic MVs in healthy rats reproduced hemodynamic,
septic inflammatory patterns, associated with oxidative and
nitrosative stresses (Mortaza et al., 2009). Conversely, we have
demonstrated that MVs possess a protective effect at the
early phase of septic shock in humans; thereby protecting
against vascular hyporeactivity (Mostefai et al., 2008). Besides,
Soriano et al. (2005) have shown that elevated levels of
circulating MVs negatively correlated with sequential organ
failure assessment score and with survival of septic patients.
Altogether, these reports suggest that, in sepsis, MVs are
effectors that participate in the pathogenesis and outcome of the
disease.
In the present study, we have evaluated the consequences
of nmMLCK deletion on MV phenotypes and their effects
on secretome of mouse aortic endothelial cells. Also, we
have analyzed their effects on vascular inflammation and
endothelial dysfunction subsequent to endotoxic shock induced
by lipopolysaccharide (LPS) in mice. For this, by using
MVsnmMLCK+/+ and MVsnmMLCK−/− in a model of cellular and
in vivo endotoxic shock, we demonstrated that MVsnmMLCK−/−
activated pro-resolving pathways by significant reduction of
in vitro pro-inflammatory secretome and in vivo improvement
of endothelial function and vascular reactivity.
MATERIALS AND METHODS
Animals
This study was performed in male C57BL/6 of 8 week-old
nmMLCK+/+ (Wild type) and nmMLCK−/− (knockout) mice
generated as previously described by selective exon targeting
(Wainwright et al., 2003). All animal care and treatment
procedures were performed in accordance with institutional
guidelines. Protocols were approved by the French Animal
Care Committee in accordance with European regulations
(CEEA.PdL2012.94).
Circulating MV Isolation
Circulating MVs were isolated from peripheral blood by
successive centrifugations. Blood was centrifuged to obtain PFP
as described (Mostefai et al., 2008). Sixty microliters of PFP
were stored at −80◦C for MV phenotyping. In order to pellet
MVs for in vitro and in vivo studies, MVs were concentrated
from PFP by centrifugation (21,000 × g, 45 min), suspended
in 0.9% NaCl and stored at 4◦C. Size of MVs was determined
by using Malvern Zetasizer (Malvern, UK). For this, 2 µl of
concentrated MVs were diluted with 300 µl of 0.9% NaCl and
proceed to the analysis. Size was comprised between 100–800 nm
which corresponds to the interval used in the definition of MVs.
The MV concentration used for in vitro and in vivo studies
corresponds to the circulating levels found in mice, whereas
the control conditions correspond to treatment by vehicle (0.9%
NaCl). MV levels were comprised between 811–3461 MV/µl of
plasma and 1174–4581 MV/µl of plasma for nmMLCK+/+ and
nmMLCK−/−, respectively.
Characterization of MV Phenotype
Regions corresponding to total MVs were identified in
forward scatter (FSC) and side scatter (SSC) intensity dot
plot representation set at logarithmic gain, depending on
their diameter (0.1–1 µm) by using calibrated beads (Flow
Cytometry Sub-micron Particle Size Reference Kit, Molecular
Probes, Eugene, OR). MV subpopulations were discriminated
in PFP according to the expression of membrane-specific
antigens by flow cytometry. MVs derived from platelets,
erythrocytes, leukocytes, and endothelial cells were labeled using
1 µg/ml CD61-FITC (clone 2C9.G2), TER119-FITC (clone
TER-119), anti-CD45-PC5 (clone 30-F11), anti-CD54-FITC
(clone YN1/1.7.4) antibodies, respectively (Biolegend, London,
UK). Anti-CD133-FITC (clone 13A4) and Sca1-PC7 (clone
D7) antibodies were used to identify progenitor-derived MVs
(Biolegend). Irrelevant mouse immunoglobulin (Ig)G was used
as an isotype-matched negative control for each sample. After
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45 min of incubation, Flow-count beads (8 µl) were added
to samples (8 µl) to measure MV concentration. Annexin-V
(BioVision, Milpitas, CA, USA) binding was used to label
phosphatidylserine using binding buffer as indicated in the
manufacturer’s protocol. Ca2+-free buffer was used to negative
control of annexin-V binding. Samples were analyzed in a
flow cytometer 500 MPL System (Beckman Coulter, Villepinte,
France).
Isolation of Aortic Endothelial Cells
Primary endothelial cells were isolated from mouse aorta
(AoECs) as previously described (Kobayashi et al., 2005; Tual-
Chalot et al., 2010). MVsnmMLCK+/+ or MVsnmMLCK−/− have
been taken from mice that have not been treated with LPS. Cells
were treated for 24 h with MVs at circulating levels detected in
the plasma of mice, in the absence or presence of LPS (Sigma-
Aldrich, St Quentin Fallavier, France; 10 µg/ml; Recoquillon
et al., 2015).
Cytokine Production
Cytokine production was evaluated by Ray Bio Mouse Cytokine
Antibody Array 3 kit (Supplementary Figure 1A; Ray Biotech,
Atlanta, GA, USA). Production of interleukin (IL)-6 and
monocyte chemoattractant protein-1 (MCP-1) was evaluated by
mouse ELISA (Ray Biotech).
Staining and Imaging of Aorta Wall by
Confocal Microscopy
Wild type mice were intravenously injected by MVsnmMLCK+/+
or MVsnmMLCK−/−. After 20 h, mice were intraperitoneally
injected with LPS (40 mg/kg) for 4 h. Then, mice were sacrificed
and thoracic aorta was isolated. In another set of experiments,
aortic rings from nmMLCK+/+ mice were treated ex vivo with
MVsnmMLCK+/+, MVsnmMLCK−/−, LPS (10 µg/ml), and LPS
with MVsnmMLCK+/+ or MVsnmMLCK−/−, for 24 h in Dulbecco’s
Modified Eagle’s medium (DMEM), 20% fetal bovine serum
(FBS), 1% antibiotics. Vessels were frozen and cut in 10 µm
sections. After fixation, tissue sections were incubated overnight
(4◦C) with anti-iNOS (BD Biosciences, San José, CA, USA), anti-
nitrotyrosine (clone 1A6, Millipore, Billerica, MA, USA), and
anti-macrophage marker (F4/80; Biolegend) antibodies. After
washes, aorta rings were incubated 1 h at room temperature
with Alexa fluor 488-labeled antibody (Interchim, Montluçon,
France). In situ production of superoxide anion was evaluated
by the fluorescent dye DHE (DHE, 3 µM, 30 min; Sigma-
Aldrich). After washes, sections were mounted on glass slides and
visualized with a confocal microscopy (CLMS 700, Zeiss, ZEN
software).
Vascular Reactivity
After different treatments, mice were sacrificed and thoracic
aorta were cleaned and cut into rings (1.5–2 mm length).
Aortic rings were mounted on a wire myograph to record
isometrical mechanical activity, as previously described
(Tual-Chalot et al., 2010; Leonetti et al., 2013). Arteries
were precontracted to 80% of maximal contraction with the
thromboxane A2 analog 9,11-Dideoxy-9a,11a-methanoepoxy
prostaglandin F2α (U-46619, Merck Chemicals, Nottingham,
UK) and endothelium-dependent relaxation was assessed by
cumulative addition of acetylcholine (1 nM–10 µM). Neither
MVsnmMLCK+/+ nor MVsnmMLCK−/− did induce differences
in the levels of pre-contraction induced by U-46619, which
attest the absence of LPS contamination on MV preparation.
Also, vascular contraction was evaluated by cumulative
application of 5-HT (5-HT, 0.1 nM–10 µM; Sigma Aldrich)
to vessels with functional endothelium (Ralay Ranaivo et al.,
2007).
Nitric Oxide (NO) Assay by Griess
Reaction
AoECs were treated with MVsnmMLCK+/+, MVsnmMLCK−/−,
LPS (10 µg/ml), or the combination LPS with MVs for 24 h.
The culture medium was collected and mixed with Griess reagent
(Sigma-Aldrich) and nitrate reductase. Sodium nitrite standards
were used to normalize the assay.
NO Spin Trapping and Electronic
Paramagnetic Resonance (EPR) Studies
The detection of NO production was performed using the
technique with Fe2+ diethyldithiocarbamate (DETC, Sigma
Aldrich) as spin trap. Isolated heart and liver from mice injected
with LPS, LPS with MVsnmMLCK+/+ or MVsnmMLCK−/−, and
vehicle were incubated for 45 min in Krebs-Hepes buffer
[bovine serum albumin (20.5 g/l), CaCl2 (3 mM) and L-arginine
(0.8 mM); Sigma-Aldrich] and after treated with 250 µl of colloid
Fe(DETC)2 and incubated at 37◦C for 45 min (Ralay Ranaivo
et al., 2007; Leonetti et al., 2013). The organs were immediately
frozen in plastic tubes. NO measurements were performed on
a tabletop x-band spectrometer miniscope (MS200; Magnettech,
Berlin, Germany). Values are expressed as amplitude of signal per
weight of dried tissue.
Data Analysis
Data were analyzed using GrapPad Prism Software (GrapPad
Software, San Diego, CA, USA). Data are expressed as
mean ± SEM, and n represents the number of mice. Statistical
analyses were performed with non-parametric Mann-Whitney
tests or two-way analysis of variance for repeated measures and
subsequent Bonferroni post hoc tests. P < 0.05 was considered to
be statistically significant.
RESULTS
Deletion of nmMLCK Protects against
the Increase in Circulating MVs as Well
as Aortic Oxidative and Nitrative Stress
and Macrophage Infiltration Induced by
LPS
Deletion of nmMLCK slightly, but significantly, increased
circulating MVs compared to wild type (Figure 1A). This
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FIGURE 1 | Deletion of non-muscular myosin light chain kinase (nmMLCK) prevents changes on MV levels induced by LPS. Circulating MVs collected
from blood were incubated with antibodies to discriminate MV subpopulations according to the expression of membrane specific antigens by flow cytometer.
Histograms show total circulating MVs (A), platelet-(CD61+) (B), endothelial cell- (CD54+) (C), erythrocyte-(TER+) (D), leukocyte-(CD45+) (E), procoagulant-(annexin
V+) (F), and progenitor cell- (CD133+, Sca1+) (G,H) MVs from nmMLCK+/+ and nmMLCK−/− mice treated intraperitoneally or not with LPS (40 mg/kg) for 4 h.
Values are expressed as events per microliters and the data represent the mean ± SEM (n = 16–21) ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. (I) Confocal image
staining of superoxide anion production by DHE (red), iNOS (green), and macrophage infiltration (F4/80 green) in thoracic aorta from nmMLCK+/+ and nmMLCK−/−
mice injected intraperitoneally by LPS (40 mg/kg) for 4 h. Histograms show fluorescence intensity of aorta DHE staining (J), iNOS (K), and F4/80 (L), assessed by
Image J. Data are expressed in arbitrary units (A.U.) of fluorescence intensity and represent the mean ± SEM (n = 3–5) ∗P < 0.05, ∗∗P < 0.01.
was associated with slight increase of procoagulant (annexin
V+) but a significant decrease of leukocytes (CD45+)-MVs
without changes in both platelets (CD61+)-, endothelial cells
(CD54+)-, and erythrocytes (TER+)-MVs (Figures 1A–F). In
addition, MVs from progenitor cells were significantly increased
(Figures 1G,H). Treatment with LPS induced an increase
in levels of circulating MVs in wild type mice especially
those derived from platelets, endothelial cells, erythrocytes, and
leukocytes without affecting procoagulant MVs (Figures 1A–F).
Interestingly, LPS failed to enhance circulating MVs in nmMLCK
deficient mice. Moreover, the increase in levels of platelet-,
endothelial-, and leukocyte-derived MVs was less pronounced
in nmMLCK−/− mice, whereas no changes were observed in
TER+-derived MVs. In accordance with our previous work
(Ralay Ranaivo et al., 2007), in vivo LPS treatment induced
increased DHE, iNOS, and F4/80 labeling in the aortic wall
from wild type whereas a slight increase was induced in
vessels from nmMLCK−/− mice (Figures 1I–L). These results
indicate that nmMLCK deletion protects against oxidative and
nitrative stress as well as macrophage infiltration induced by LPS
(Figures 1G–J).
MVs from nmMLCK−/− Mice Have No
Effects on Mouse AoECs or Aorta with
Respect to Inflammatory Cytokine
Release, Oxidative, and Nitrative
Stresses as Well as Endothelial Function
In order to decipher whether MVs from nmMLCK−/− mice
participate in mechanism of protection against LPS treatment,
we first examined the effects that these MVs on their own.
Thus, we analyzed by antibody array screening the effect of
MVsnmMLCK−/− on inflammatory cytokines on mouse AoECs
(Figure 2A). Treatment with MVsnmMLCK−/− enhanced the
production of MCP-1 by AoECs without affecting secretion of
other cytokines such as IL-4, IL-5, or IL-6 (Figures 2A–C). In
addition, no significant changes on nitrite/nitrate production
reflecting nitrative stress were observed in AoECs after treatment
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FIGURE 2 | Lack of effects of circulating MVs from non-muscular myosin light chain kinase (nmMLCK)-deficient mice. Primary endothelial cells isolated
from mouse aorta (AoECs) of nmMLCK+/+ mice were treated for 24 h with MVsnmMLCK−/−. Cytokine production was evaluated by Ray Bio Mouse Cytokine
Antibody Array 3 kit (Supplementary Figure 1A). (A) Histograms show the cytokine ratio between either MVsnmMLCK−/−-treated versus non-treated cells (Control).
Black line represents cytokine production of non-treated cells. Results are expressed as a percentage of relative intensity of spots (%). Data represent the mean of
n = 3. Quantification of MCP1 (B) and IL-6 (C) secretion by ELISA assay. Data represent the mean of n = 3, ∗P < 0.05. (D) Quantification of NO−2 /NO−3
(nitrite/nitrate) from the supernatant of AoECs previously treated by MVsnmMLCK−/−, using Griess assay. (E–H) Confocal image staining of superoxide anion
production by DHE (red), iNOS (green), and nitrotyrosine expression (green) in mouse wild type aorta exposed 24 h ex vivo to either saline salt solution (Ctl) or
MVsnmMLCK−/−. Aorta was imaged using confocal microscope. (F–H) Histograms show fluorescence intensity of aortic DHE staining (F), iNOS (G) and nitrotyrosine
(H) assessed by Image J. Background fluorescence intensity was subtracted using unstained aortas. Data are expressed in arbitrary units (A.U.) of fluorescence
intensity and represent the mean ± SEM (n = 3–5). (I–L) Confocal image staining of DHE (red), iNOS expression (green), and macrophage infiltration (F4/80 green) in
aorta from wild type mice injected intravenously with saline salt solution (Ctl) or MVsnmMLCK−/− for 24 h. Histograms show fluorescence intensity of aortic DHE
staining (J), iNOS (K) and F4/80 (L), assessed by Image J. Data expressed in A.U. of fluorescence intensity and represent the mean ± SEM (n = 3–5).
(M) Endothelium-dependent relaxation induced by acetylcholine (Ach) was evaluated by myography on aortic rings from wild type mice treated intravenously with
MVsnmMLCK−/− at their circulating concentration. The relaxation was expressed as a percentage of precontraction level. Statistical analyses were performed using
two-way ANOVA test. Data represent the mean of n = 3.
by MVsnmMLCK−/− (Figure 2D). When aortic rings from wild
type mice were in vitro incubated with MVsnmMLCK−/− no
significant changes in inflammatory markers (DHE, iNOS) or
nitration of proteins were observed (Figures 2E–H). Also,
when mice were injected with MVsnmMLCK−/−, no effects
were detected concerning oxidative and nitrative stresses or
macrophage infiltration (Figures 2I–L).
Aortic rings from nmMLCK+/+ mice relaxed in response to
acetylcholine up to a maximum of relaxation at 10 µM (60% of
relaxation; Figure 2M). Treatment with MVsnmMLCK−/− did not
modify the relaxation induced by acetylcholine. Altogether, these
results suggest that MVsnmMLCK−/− by themselves do not induce
inflammation nor modify vascular function.
MVsnmMLCK−/− Protect against the
Effects of LPS-Induced Inflammation by
Increasing Anti-Inflammatory and
Reducing Pro-Inflammatory Secretome
in AoECs
First, the cytokine contents of MVs from wild type and
nmMLCK-deficient mice were assessed. No significant
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FIGURE 3 | Microvesicles from non-muscular myosin light chain kinase-deficient mice (MVsnmMLCK−/−) increase anti- inflammatory and reduce
pro-inflammatory secretome of aortic endothelial cells (AoECs). Primary AoECs from wild type mice were treated for 24 h with MVsnmMLCK+/+ or
MVsnmMLCK−/− in the absence or in the presence of LPS (10 µg/ml). Cytokine production was evaluated by Ray Bio Mouse Cytokine Antibody Array 3 kit
(Supplementary Figure 1A for more details). Data represent the mean ± SEM (n = 3–5). (A,B) Histograms show the cytokine ratio between either
LPS+MVsnmMLCK+/+-treated versus LPS-treated cells or LPS+MVsnmMLCK−/−-treated versus LPS-treated cells. Black line represents no change in cytokine
production between treatments. Results are expressed as a percentage of relative intensity of spots (%). Data represent the mean of three experiment (n = 3–5).
†P < 0.05.
differences on the cytokine content were observed between
both types of MVs (Supplementary Figure 1B).
In the presence of LPS, MVsnmMLCK+/+ increased the
production of pro-inflammatory cytokines such as CD40,
IL-1β, tumor necrosis factor alpha (TNFα), IL-12P70 active
form of IL-12 cytokine (observed also by decreased ratio
IL12P40/P70, IL12P40 antagonist form of IL12P70), and SDF
(SDF-1α; Figures 3A,B). Furthermore, MVsnmMLCK+/+
reduced anti-inflammatory cytokine (IL-10), and pro-
inflammatory chemokines (TECK, MIG; Figure 3B). In
contrast, MVsnmMLCK−/− induced a lower increase of TNFα,
CRG2, and G-CSF and a higher enhancement of IL-12P70
and SDF-1α than MVsnmMLCK+/+ treatment (Figure 3B).
Interestingly, MVsnmMLCK−/− enhanced the release of
anti-inflammatory cytokines (IL-4 and IL-5), IGFBP-3, and
lymphocyte chemokines (lymphotactin and TARC; Figure 3B).
Moreover, MVsnmMLCK−/− decreased several pro-inflammatory
cytokines (TIMP1, IFNγ, IL-17, MIP family, P-selectin, Rantes,
VCAM1; Figure 3B). These results show that the protective effect
of MVsnmMLCK−/− against the deleterious effects of LPS was
associated to their ability both to increase anti- inflammatory
and to reduce pro-inflammatory secretome in AoECs.
MVsnmMLCK−/− Prevent Oxidative and
Nitrative Stresses Induced by In vitro
Treatment with LPS on Mouse Aorta
As expected, LPS incubation significantly increased O−2
production, iNOS expression and nitration of tyrosine in
aortas from wild type mice (Figures 4A–D). In the presence
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FIGURE 4 | Microvesicles from non-muscular myosin light chain kinase-deficient mice (MVsnmMLCK−/−) reduce the LPS-evoked oxidative and
nitrative stresses in mouse aorta. (A) Confocal image staining of DHE (red), iNOS (green), and nitrotyrosine expression (green) in mouse wild type aorta exposed
24 h ex vivo to saline salt solution, LPS alone (10 µg/ml), LPS + MVsnmMLCK+/+ or LPS + MVsnmMLCK−/−. Aorta was imaged using confocal microscope. (B–D)
Histograms show fluorescence intensity of aorta DHE staining (B), iNOS (C), and nitrotyrosine (D) assessed by Image J. Data represent arbitrary units (A.U.) of the
mean ± SEM (n = 3–5). ∗P < 0.05, ∗∗P < 0.01.
of LPS, MVsnmMLCK+/+ did not modify the DHE labeling,
iNOS expression, and nitrotyrosine levels when compared to
the LPS alone (Figures 4A–D). Interestingly, MVsnmMLCK−/−
prevented the effect of LPS to induce O−2 production and tyrosine
nitration and partially reduced iNOS overexpression in the aorta
(Figures 4A–D). These responses were reinforced by the fact
that LPS was not able to increase nitrite/nitrate and nitration
of proteins in the presence of MVsnmMLCK−/− in AoECs (not
shown).
MVsnmMLCK−/− Correct Ex vivo
Deleterious Effect of LPS on Vascular
Function and In vivo NO Production in
Heart and Liver
As expected, treatment with LPS induced significant reduction
of the maximal of relaxation (∼80% of inhibition) compared
to vessels taken from vehicle-injected animals, which traduces
endothelial dysfunction (Figure 5A). MVsnmMLCK+/+ injection
did not modify the LPS-induced impairment on endothelial
relaxation. Interestingly, MVsnmMLCK−/− partially corrected the
effect of LPS on the endothelium-dependent relaxation induced
by acetylcholine. In addition, hyporeactivity induced by LPS
was partially corrected by both types of MVs; however, the
effects of MVsnmMLCK−/− were significantly higher than those
of MVsnmMLCK+/+ (Figure 5B).
Also, whereas MVsnmMLCK+/+ had not effect or partially
reduced LPS-evoked NO production in heart and liver,
respectively, MVsnmMLCK−/− abolished the increase in
NO production induced by LPS treatment in these tissues
(Figures 5C,D). Together, these results suggest that deletion
of nmMLCK leads to protective effects of MVs to correct LPS
inflammation.
DISCUSSION
Here, we show that nmMLCK-deficient mice display a resistance
to LPS-induced increase in circulating MVs and vascular
oxidative/nitrative stress and macrophage infiltration. Most
importantly, we provide evidence that MVs issued from
nmMLCK-deficient mice prevent the inflammatory effects of
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FIGURE 5 | Microvesicles from non-muscular myosin light chain kinase-deficient mice (MVsnmMLCK−/−) improve the vascular function induced by
LPS in vivo and the nitrative stress in heart and liver. Wild type mice were injected intravenously with saline salt solution (Ctl), MVsnmMLCK+/+, or
MVsnmMLCK−/−. After 20 h, mice were injected intraperitoneally with LPS (40 mg/Kg) for 4 h. (A) Endothelium-dependent relaxation induced by acetylcholine (Ach)
was evaluated by myography. The relaxation was expressed as a percentage of precontraction level. (B) Concentration-effect curves in response to 5-HT in aortic
rings isolated from mice. Contraction are expressed in mN/mm. (C,D) NO production assessed by the amplitude of NO-Fe(DETC)2 complex signal in unit/weight in
heart (C) and liver (D) from mice. Data represent arbitrary units (A.U.) of the mean ± SEM/mg of tissue weight (n = 3–5). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
LPS with concomitant increase of anti- inflammatory and
reduction of pro-inflammatory secretome from endothelial cells.
In addition, MVsnmMLCK−/− lead to a reduced efficacy of
LPS to increase aortic oxidative and nitrative stress as well as
macrophage infiltration in the aorta. Moreover, MVsnmMLCK−/−
correct ex vivo deleterious effect of LPS on endothelial function,
vascular reactivity, and in vivo tissular overproduction of NO.
Altogether, these findings provide evidence that nmMLCK
deletion generates circulating MVs displaying protective effects
by activating pro-resolving anti-inflammatory pathways allowing
the effective down-regulation of oxidative and nitrative stresses
associated with endotoxic shock.
Sepsis in general, and endotoxic shock in particular,
is characterized, at the vascular level, by an increase of
inflammation resulting from an enhanced secretion of cytokines
and chemokines, an exacerbated production of reactive oxygen
species, and the induction of iNOS leading to enhanced
NO production which accounts for vascular hyporeactivity
and endothelial dysfunction. These events favor macrophage
infiltration on the vessel wall and finally lead to organ failure
(for review see Sherwood and Toliver-Kinsky, 2004). We have
previously reported that, in several models of endotoxemia
(LPS and cecal ligation puncture), nmMLCK−/− mice are
protected against nitrative and oxidative stresses at the level
of the vascular wall and the subsequent increase of survival
when compared to wild type mice (Ralay Ranaivo et al., 2007).
Here, we show that LPS treatment increase MV formation
in wild type mice and, interestingly, nmMLCK−/− mice are
protected against this increase. Enhanced levels of circulating
MVs from platelets, granulocytes, and endothelial cells have
been described in patients with meningococcal septicemia, and
septic shock (Nieuwland et al., 2000; Fujimi et al., 2002; Mostefai
et al., 2008). MVs participate in organ dysfunction observed
in septic shock patients (Mastronardi et al., 2011) despite the
reported correlation between increased circulating MPs and
better survival rate among patients in the early phase of septic
shock (Soriano et al., 2005). Also, inoculation of septic MVs
in healthy rats reproduced hemodynamic, septic inflammatory
patterns, associated with oxidative and nitrative stresses (Mortaza
et al., 2009). Thus, the prevention of increase of circulating MVs
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by nmMLCK deletion may participate in the correction of the
deleterious effect of LPS at the level of the vascular wall.
On the other hand, the present results suggest that nmMLCK
is probably implicated on the process of MV formation. It is well
known that cytoskeleton disorganization represents an essential
step in the process of MV generation, and at this level, nmMLCK
may interact with other cytoskeleton proteins and contribute
to the MV formation (Owens and Mackman, 2011). Indeed,
several studies have shown that inhibition of MLCK with ML-
7 reduces MV production suggesting that MLCK participates
in the process of membrane blebbing leading to MV formation
and/or release (Mills et al., 1998; Muralidharan-Chari et al.,
2009; Midura et al., 2016). It has been shown that activation of
MLCK by Ca2+/calmodulin or by tyrosine kinase phosphorylated
regulatory MLC-2 resulting in a change in the myosin tertiary
structure favoring contractile movement against actin at the
necks of MVs, facilitating their release into the extracellular
space (Muralidharan-Chari et al., 2009). At the opposite, recent
data show that ML-7 increases the number of blebs/min/cell
suggesting that MLCK controls membrane dynamics (Barfod
et al., 2011), that is in agreement with the present results
demonstrating that the deletion of nmMLCK increased the
number of circulating MVs. The increase in the number of
circulating MVs was not probably due to their decreased
clearance on nmMLCK−/− mice because alterations on in vitro
production of platelet-derived MVs from nmMLCK−/− mice
were also observed (data not shown).
In the present study, we showed that MVs may modulate
the secretion of inflammatory mediators from endothelial cells
by LPS. Modification of the secretory capacity of endothelial
cells alters the function of these cells leading, in the long run,
to the development of cardiovascular diseases (Libby, 2000).
Whereas MVs from nmMLCK+/+ mice increased the release
of pro-inflammatory versus anti-inflammatory cytokines, MVs
from nmMLCK−/−mice induced opposite effects suggesting that
both types of MVs are able to regulate cytokine production in
endothelial cells but they activate different pathways in order
to produce different cytokines. It is accepted that MVs can
harbor cytokines to be transfer into the target cells. Thus, it has
been shown that human monocytes treated by LPS were able
to release MVs carrying bioactive IL-1β and transcripts for pro-
inflammatory cytokines such as TNF, IL-6, and IL-8 (MacKenzie
et al., 2001; Wen et al., 2014). However, in the present study
we have described that MVs from both wild type and nmMLCK
knock out mice harbor identical cytokine contents. Other authors
have reported that MVs released by human endothelial cells
and monocytes after TNF-α stimulation up-regulated podocyte
production of pro-inflammatory MCP-1 and IL-6 (Eyre et al.,
2011). Interestingly, under pro-inflammatory conditions such
as LPS infusion, injection on systemic circulation of MVs
generated in vitro from human endothelial cells increased levels
of IL-1β and TNF-α, suggesting that MVs prime injury-associated
inflammation in mice (Buesing et al., 2011). In contrast, other
types of MVs possessed anti-inflammatory and beneficial effects.
Activated human neutrophils released MVs were able to reduce
inflammatory response mediated by macrophages exposed to LPS
(Gasser and Schifferli, 2004) by mechanism related to annexin
A1 (Dalli et al., 2008). Similarly, MVs enriched in alpha-2-
macroglobulin preserved neutrophil chemotactic responses in
the presence of LPS and consequently activated pro-resolving
pathways (Dalli et al., 2014). Here, the protective effects of
MVs from nmMLCK−/− mice may be related with a different
composition of MVs. Indeed, as described above, deletion of
nmMLCK can affect not only the process of MV formation but
also their content. In this respect, nmMLCK has been reported to
contain amino acid sequence motifs associated with subcellular
targeting or protein-protein interactions in the proteome (Lin
et al., 1999; Smith et al., 2002). This domain of the enzyme
plays a role as a cellular organizer, providing integration among
diverse protein including cytoskeletal proteins (Kudryashov
et al., 2004) and NF-κB (Recoquillon et al., 2015). Congruent
with that hypothesis, MLCK activity has been shown to drive
TNFα-dependent NF-κB activation and amplification. Thus, cells
from nmMLCK-deficient mice might not able to activate this
pathway and modify the generated MVs to be less inflammatory.
Interestingly, we demonstrate that MVsnmMLCK−/− partially
corrected, at the level of vascular wall, inflammatory responses
elicited by LPS in in vitro and in in vivo conditions. Indeed,
MVsnmMLCK−/− reduced iNOS expression, superoxide anion
production, and macrophage infiltration into the vascular wall.
At a consequence, MVsnmMLCK−/− restore vascular function
after LPS treatment since endothelium-dependent relaxation
and vascular contraction were improved. Furthermore, nitrative
stress in vital organs such as heart and liver were abolished,
suggesting that MVsnmMLCK−/− act, not only at the vascular
level, but also in other organs essential to maintain life. Our
previous study shows that nmMLCK is involved in lethal
complications as well as in the vascular reactivity changes
associated with endotoxic shock (Ralay Ranaivo et al., 2007).
nmMLCK is linked to LPS-induced up-regulation of NF-κB and
increased oxidative and nitrative stresses (Recoquillon et al.,
2015). The present study and our former reports underscore
that inoculation of MVs from nmMLCK-deficient mice into
wild type mice or the use of nmMLCK-deficient mice display
similar protective effect in the experimental model of endotoxic
shock used in terms of oxidative/nitrative stress, vascular and
tissular dysfunction. We further demonstrate that nmMLCK
plays a role in the deleterious messages carried by MVs leading
to increased susceptibility to sepsis and its consequences in both
cardiovascular and systemic injuries.
Limitations of the Study
Up to now, nmMLCK has been involved in the regulation
of the endothelial cell permeability by regulating cytoskeletal
rearrangement through the ATP-dependent interaction of actin
and myosin on endothelial cells (Shen et al., 2010). Deletion
of nmMLCK affects the production of MVs and probably their
content. Further studies are needed to fully characterize the
composition of MVsnmMLCK−/−, and in this way, to decipher
the exact mechanism implicated in the opposite effects of MVs
depending on their origin (nmMLCK wild type or knock out
mice). Because cytokine content of both types of MVs is not
different, we can hypothesize that MVsnmMLCK−/− might carry
transcription factors or miRNA presenting anti-inflammatory
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functions which contribute to reduce inflammatory effect of LPS
on target cells.
Besides, therapy with engineered nmMLCK-deleted MVs may
represent an important tool of personalized medicine since these
MVs display anti-inflammatory properties. Thus, they could well
represent new and promising therapeutic strategies and these
results may be transposed to sepsis in humans.
CONCLUSION
This study provides evidence that deletion of nmMLCK generates
circulating MVs with a protective potential. They underscore
that nmMLCK may represent a candidate in the regulation of
pro-resolving responses in sepsis by engineered MVs.
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